No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ARCT240517P30000
- 1.80
- -2.60-59.09%
15min DelayTrading May 13 12:02 ET
1.80High1.80Low
1.80Open4.40Pre Close20 Volume29 Open Interest30.00Strike Price3.60KTurnover65.90%IV-0.91%PremiumMay 17, 2024Expiry Date1.49Intrinsic Value100Multiplier4DDays to Expiry0.31Time Value100Contract SizeAmericanOptions Type-0.7402Delta0.1557Gamma16.29Leverage Ratio-0.0742Theta-0.0025Rho-12.06Eff Leverage0.0103Vega
Intraday
- 5D
- 1D
News
Arcturus Therapeutics (NASDAQ:ARCT) Making Significant Strides Towards Growth
Arcturus Therapeutics Is Maintained at Buy by Canaccord Genuity
Arcturus Therapeutics Is Maintained at Buy by Canaccord Genuity
Express News | Canaccord Genuity Maintains Buy on Arcturus Therapeutics, Lowers Price Target to $86
Arcturus Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 219.47% Canaccord Genuity $87 → $86 Maintains Buy 03/20/2024 122.88% HC Wainwright & Co. → $60
Buy Rating Affirmed for Arcturus Therapeutics Amidst Strong Financial Outlook and Promising Clinical Advancements
Earnings Call Summary | Arcturus Therapeutics(ARCT.US) Q1 2024 Earnings Conference
The following is a summary of the Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2024 Earnings Call Transcript:Financial Performance:Arcturus reported Q1 2024 revenues of $38 million, an increase from
Comments
Analysts maintain loss per share estimates for next year with no major changes to revenue estimates. However, the company's performance is expected to underperform the wider industry. The steady consensus price target indicates that reduced loss estimates may not positively impact the stock's long-term valuation.
Analysts Have Made A Financial Statement On Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Yearly ReportDespite Arcturus Therapeutics Holdings Inc.'s strong run, its P/S ratio remains low due to a weak revenue outlook. Investors believe the potential for revenue improvement doesn't justify a higher P/S ratio, forming a barrier for the share price.
The recent improvement in total shareholder return could indicate that the business is getting better over time. However, there are 2 warning signs that investors should be aware of. The sentiment around the company seems to be positive lately.
Read more